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observational study was conducted prospectively in a parallel
group design. In 22 hospitals, 580 patients were enrolled, 261
patients in the moxiﬂoxacin-(M-)cohort and 319 patients in the
standard-(S-)cohort of other antibiotics. The economic perspec-
tive of a German hospital was applied for the cost measurement.
After conduct of the study, the patient data were grouped into
the relevant German DRG and the course of treatment, costs and
reimbursement of both cohorts were analysed. RESULTS: The
outcome of the patients at the beginning of treatment was com-
parable in both cohorts. The length-of-stay of the patients was
signiﬁcantly shorter in the moxiﬂoxacin cohort for the more
severe DRGs E62A (M-cohort 10.1 days, N = 113; S-cohort 12.2
days, N = 164; p = 0.004) and E62B (M-cohort 9.7 days, N =
112; S-cohort 10.7 days, N = 146; p = 0.041). In the third DRG
E62C no differences were found (M-cohort 10.2 days, N = 36;
S-cohort 9.4 days, N = 9; p = 0.306). Net proﬁt per case for the
hospitals in the DRG E62A was 1931€ and 1683€ for the cohorts
M and S respectively (E62B: M 1365€, S 1296€; E62C: M 802€,
S 791€). CONCLUSIONS: For the treatment of hospitalised
CAP the study demonstrated the economical relevance of fast
recovery secondary to efﬁcacious drug therapy. Under current
reimbursement modalities the treatment with moxiﬂoxacin is
more proﬁtable from the hospitals’ perspective due to a short-
ened length of stay of the patients.
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OBJECTIVES: Since the beginning of 2004, the diagnosis-related-
groups (DRG) are implemented in the reimbursement procedure
for German hospitals representing a signiﬁcant change for the
hospitals economic situation. As an example for non-invasive
treatment procedures in a German hospital, a prospective health
economic study evaluated the treatment costs of community-
acquired pneumonia (CAP) from the hospital’s perspective.
Results of an interim analysis were published in 2003, now the
ﬁnal results of the study are presented. METHODS: Open, non-
randomized prospective observational study from the perspective
of the German hospital administration. In 11 study centres, 319
patients were enrolled. A process-cost-analysis was performed to
determine the costs for the German hospital sector starting from
the admission up to the discharge of the patient. The cost calcu-
lation comprises diagnostic and therapeutic measures, drugs,
hotel costs and nursing. Both personnel costs and material costs
were included. Acquisition of medical devices was not included
into the analysis. RESULTS: The patients enrolled suffered from
moderate to severe stages of CAP with a mean length-of-stay of
11.5 days (peripheral ward: 10.7; ICU 0.8). Mean costs per
patient amounted to 1528€ (SD: 1011€). Most important cost-
driving factors were hotel costs (640€) and nursing (554€). Drug
acquisition cost resulted in 201€, whereas costs for diagnostics
(80€) and therapeutic measures (54€) were comparatively low.
The most often applied drugs were macrolides (37.6% of the
patients), b-lactamase inhibitor-aminopenicillin combinations
(32.3%), and cephalosporins of 2nd (30.4%) and 3rd generation
(28.5%). Thirty-six patients (11.3%) died during the hospital
stay. CONCLUSIONS: In hospitalised CAP, length of stay deter-
mines the costs from the economic perspective of the hospital,
which underlines the importance of a reduction of length of stay
in this indication. The need for rapid and safe antibiotic treat-
ment becomes evident especially under consideration of the DRG
reimbursement system.
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OBJECTIVE: To estimate health care costs for the treatment of
acute exacerbation of chronic bronchitis (AECB) and commu-
nity-acquired pneumonia (CAP) in 4 previously-reported Phase
III multinational comparative trials of telithromycin vs 
amoxicillin-clavulanic acid and clarithromycin in Canada.
METHODS: In each of the 4 studies, patients were followed for
1 month and the primary endpoint was clinical efﬁcacy at the
posttherapy/test of cure (TOC) visit. Each trial prospectively col-
lected data on study indication-related hospitalizations, addi-
tional health care provider visits, and additional antibiotic
therapy. Three trials also collected information on additional lab-
oratory and other tests and procedures. Cost analyses were per-
formed from the perspective of the Ontario Ministry of Health.
RESULTS: A total of 1045 and 853 patients in the 4 trials were
randomized to receive telithromycin or a comparator, respec-
tively. At baseline, the patient groups were similar with respect
to demographic and clinical characteristics. The clinical efﬁcacy
of telithromycin and the comparators was similar in each study.
Compared to patients randomized to comparator, those ran-
domized to telithromycin were less likely to require AECB- and
CAP-related hospitalization. Total and average costs of care were
approximately 2 to 3 times higher in the comparator groups,
driven by higher hospitalization rates. The ratio of average total
treatment cost per patient in each comparator to that of
telithromycin was as follows: $40/$19 = 2.1 for amoxicillin-
clavulanic acid in AECB; $241/$122 = 1.9 for clarithromycin in
AECB; $198/$109 = 1.8 and $293/$90 = 3.3, for clarithromycin
in CAP. CONCLUSION: Although clinical cure rates for
telithromycin, amoxicillin-clavulanic acid, and clarithromycin
are comparable, health care costs appear to be lower among
patients taking telithromycin, a ﬁnding driven by fewer hospi-
talizations. Since hospitalization accounts for a major propor-
tion of the direct health care costs associated with AECB and
CAP in Canada, the use of telithromycin may signiﬁcantly reduce
the total costs of care for these respiratory conditions.
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OBJECTIVES: COPD is a chronic disease that causes disability
and increases with age. The aim was to assess the quality of life
of COPD patient treated in Primary Assistance in Spain.
